financetom
Business
financetom
/
Business
/
Kayne Anderson Bdc, Inc IPOs Tomorrow, Here's What You Need To Know
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kayne Anderson Bdc, Inc IPOs Tomorrow, Here's What You Need To Know
May 21, 2024 8:32 AM

Kayne Anderson BDC, Inc ( KBDC ) IPO will take place May, 22 on the NYSE exchange under the ticker KBDC.

The company is offering shares at an expected price of $16.63 per share with an insider lock-up period of 180 days ending on November 18, 2024.

See also: Benzinga IPO Calendar

About Kayne Anderson BDC, Inc

Kayne Anderson is a business development company ("BDC") that invests primarily in first lien senior secured loans with a secondary focus on unitranche and split-lien loans to private middle market companies.

See also: Benzinga's Most Shorted Stocks

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Satellos Bioscience Q3 Net Loss Narrows
Satellos Bioscience Q3 Net Loss Narrows
Nov 14, 2025
07:53 AM EST, 11/14/2025 (MT Newswires) -- Satellos Bioscience ( MSCLF ) Friday said third-quarter net loss narrowed. Net loss improved to US$5.8 million, or $0.03 per share, from a loss of $6.6 million, or $0.06 per share, for the prior year period. The result was inline with the $0.03 loss forecast by analysts, according to FactSet. The decrease in...
Form 8.3
Form 8.3
Nov 14, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Twist Bioscience Fiscal Q4 Net Loss Narrows, Revenue Rises; Fiscal Q1, 2026 Revenue Outlook Issued
Twist Bioscience Fiscal Q4 Net Loss Narrows, Revenue Rises; Fiscal Q1, 2026 Revenue Outlook Issued
Nov 14, 2025
07:47 AM EST, 11/14/2025 (MT Newswires) -- Twist Bioscience ( TWST ) reported Friday a fiscal Q4 net loss of $0.45 per diluted share, narrower than a loss of $0.59 a year earlier. Three analysts polled by FactSet expected a loss of $0.43. Revenue for the quarter ended Sept. 30 was $99 million, up from $84.7 million a year earlier....
Form 8.3
Form 8.3
Nov 14, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved